Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Coronavirus Disease-2019 and Implications on the Liver

Patrick T. Campbell, MD, Oren K. Fix, MD, MSc*

KEYWORDS
- Cirrhosis • Immunosuppression • SARS-CoV-2 • Transplant • Vaccination

KEY POINTS
- The coronavirus disease-2019 (COVID-19) pandemic has had a substantial impact on patients with chronic liver disease (CLD) and liver transplantation (LT) recipients.
- The management of many CLD has been significantly altered by the COVID-19 pandemic.
- Vaccination against COVID-19 protects patients with CLD and LT recipients from adverse outcomes and is safe in these patients.
- Vaccine efficacy may be reduced in LT recipients and other immunosuppressed patients.

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that is responsible for causing coronavirus disease-2019 (COVID-19). SARS-CoV-2 was first detected in humans in late 2019 and spread to become a worldwide pandemic. This virus is most similar to the beta-coronaviruses, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), that were responsible for the SARS outbreak in 2002 to 2003 and the MERS outbreak in 2012, respectively. SARS-CoV-2 primarily causes upper respiratory tract infections and pneumonia. Severe cases can lead to acute respiratory distress syndrome and death. Although the lung manifestations are the most common and most severe, SARS-CoV-2 has effects on other organs including the liver and gastrointestinal tract. The aim of this article is to review the effects of SARS-CoV-2 on the liver and how COVID-19 and the resulting pandemic have altered the outcomes and management of chronic liver diseases (CLDs) and liver transplantation (LT).
EFFECTS OF CORONAVIRUS DISEASE-2019 ON THE LIVER

Abnormalities in liver biochemistries are common in patients with COVID-19, with a highly variable prevalence of 14% to 83% in hospitalized patients and occurring more frequently in severe COVID-19.\textsuperscript{1-5} Liver biochemical abnormalities are most commonly characterized as mild elevations of alanine transaminase (ALT) and aspartate transaminase (AST) (<5 times the upper limit of normal [xULN]). Bilirubin is usually normal or only slightly elevated and alkaline phosphatase/gamma-glutamyl transferase elevations are uncommon (occurring in 6% and 21% of patients, respectively).\textsuperscript{6} AST levels do not correlate with markers of muscle breakdown (creatine kinase) or systemic inflammation (C-reactive protein and ferritin), suggesting that elevations seen in the setting of COVID-19 may be due to direct liver injury.\textsuperscript{7} However, the incidence of liver biochemical abnormalities in patients with COVID-19 does not seem to be associated with the presence of preexisting CLD.\textsuperscript{8} The aminotransferase elevation in COVID-19 is often AST-predominant, which is similar to alcohol-related liver disease and ischemic hepatitis.\textsuperscript{7} The pattern of AST-predominant aminotransferase elevation has also been associated with COVID-19 disease severity.\textsuperscript{4} The reason for AST predominance is unclear but could be related to hepatic hypoperfusion from COVID-19-induced microthrombotic disease\textsuperscript{9} or systemic hypoxia. The fact that similar AST-predominant elevations were reported during the 2009 influenza H1N1 outbreak could support the hypothesis that systemic hypoxia is the underlying driver of this liver enzyme pattern.\textsuperscript{10} Low albumin levels in the setting of COVID-19 can also be seen and correlate with more severe COVID-19.\textsuperscript{11} Severe liver injury, defined as elevations in total bilirubin and/or evidence of synthetic dysfunction, is uncommon but associated with poorer clinical outcomes.\textsuperscript{5} Given the frequency of elevated liver biochemistries in patients hospitalized with COVID-19, it is recommended that liver biochemistries be monitored regularly in this patient population.\textsuperscript{12}

There can be many reasons for elevated liver biochemistries in patients with COVID-19, including muscle breakdown in the setting of myositis or cardiac injury, direct hepatic infection with SARS-CoV-2, hepatic ischemia caused by hypotension or thrombosis, cytokine release syndrome/immune-mediated injury, post-COVID cholangiopathy, and drug-induced liver injury (DILI) (Fig. 1). Given the broad differential, determining the exact cause of the elevated liver biochemistries in a patient with COVID-19 can be challenging and the cause is often multifactorial. Fig. 2 offers a proposed algorithm for the evaluation of abnormal liver tests in the patient with COVID-19.

\textbf{Fig. 1.} Potential causes of COVID-19-related liver injury. DILI, drug-induced liver injury.
Direct Hepatic Infection via Angiotensin-Converting Enzyme 2 and/or Dipeptidyl Peptidase 4

SARS-CoV-2 binds to cells using angiotensin-converting enzyme 2 (ACE2) as a receptor and is subsequently internalized. In the liver, ACE2 is found on cholangiocytes, sinusoidal epithelial cells, and hepatocytes. Direct viral infection of hepatocytes and cholangiocytes is one potential mechanism for COVID-19-induced hepatic injury because of the presence of ACE2 on these cells. Gene expression of ACE2 is greatest in cholangiocytes with levels that are comparable to alveolar type 2 cells in the lung. Autopsy results from patients with COVID-19 have shown the presence of SARS-CoV-2 within hepatocytes confirming that hepatic infection by SARS-CoV-2 does occur, likely via ACE2. Hepatic ACE2 levels are significantly upregulated in several CLDs including hepatitis C virus (HCV) (30-fold increase) and nonalcoholic steatohepatitis (NASH) (compared with those with simple steatosis), potentially predisposing these patients to more frequent and/or significant liver injury caused by COVID-19.

Another enzyme that may be responsible for direct hepatic insult from COVID-19 is dipeptidyl peptidase-4 (DPP-4). MERS-CoV is known to use DPP-4 as a receptor for cell entry and SARS-CoV-2 can also use DPP-4 as a receptor. DPP-4 is found in most organs but is present in particularly high levels in the liver. It is often upregulated in diabetes and the metabolic syndrome, which are frequently present in NASH. DPP-4 may also play a role in hepatic fibrosis. Although these findings may suggest a possible mechanism of direct COVID-19-related liver injury, whether DPP-4 is truly responsible for elevated liver biochemistries in patients with COVID-19 is still unproven.

Thrombosis and Ischemia

Another possible mechanism of liver injury during COVID-19 is due to a prothrombotic state leading to microthrombi and resulting ischemia. It has been well documented that COVID-19 produces a hypercoagulable state that increases the risk of thrombosis and microvascular thrombosis. Autopsy studies of patients who died from COVID-19 have discovered the presence of microthrombi in several organs including the liver. In one study, liver biopsy samples from 48 patients who died from COVID-19 showed evidence of microthrombi and ischemic changes.

Fig. 2. Algorithm for the evaluation of abnormal liver biochemistries in the patient with COVID-19. DILI, drug-induced liver injury; MRCP, magnetic resonance cholangiopancreatography; ULN, upper limit of normal.
severe COVID-19 revealed portal venous and sinusoidal microthrombi in all patients. A meta-analysis of several autopsy studies found a lower, but still significant, prevalence of hepatic vascular thrombosis (29%). This study also reported cases of hepatic venous outflow obstruction and phlebosclerosis of the portal vein.

**Immune-Mediated Injury**

COVID-19 is known to cause a significant pro-inflammatory response and cytokine release syndrome; therefore, an immune-mediated injury may be contributing to elevated liver biochemistries in patients with COVID-19. Patients with COVID-19 with elevated liver biochemistries are more likely to have fever, higher levels of pro-inflammatory markers (C-reactive protein and procalcitonin), and higher lactate dehydrogenase. However, further study is needed to determine if COVID-19 truly causes an immune-mediated liver injury.

**Post-Coronavirus Disease Cholangiopathy**

Cholangiopathy has been described as a rare, late liver-related complication of severe COVID-19. In one study of 2047 patients who were hospitalized with COVID-19, 12 patients with severe COVID-19 developed cholangiopathy. The imaging and histologic findings in these patients were similar to the previously described secondary sclerosing cholangitis in critically ill patients (SSC-CIP). Typical magnetic resonance cholangiopancreatography findings in these patients included beading of intrahepatic bile ducts and bile duct wall thickening with enhancement. Several patients underwent liver biopsy that showed large bile duct obstruction without bile duct loss. The average time to cholangiopathy diagnosis was 118 days after initial COVID-19 diagnosis. Five of these patients were eventually evaluated for LT because of persistent jaundice, hepatic dysfunction, and/or recurrent episodes of bacterial cholangitis, and one did eventually undergo LT. The underlying pathogenesis explaining why post-COVID cholangiopathy occurs is not currently understood and further study in this area is needed.

**Effect of Coronavirus Disease-2019-Directed Therapies on the Liver**

DILI is a frequent cause of elevated liver biochemistries in hospitalized patients with COVID-19, including two COVID-19-directed therapies, remdesivir, and tocilizumab, that have been implicated as possible causes of DILI in patients with COVID-19.

Remdesivir, a viral RNA polymerase inhibitor, was one of the first drugs to show efficacy against COVID-19. The earliest studies of compassionate-use remdesivir showed that elevated liver biochemistries were the most frequently reported adverse event. Compared with placebo, patients receiving remdesivir more frequently had treatment discontinued for elevated transaminases or bilirubin. However, these studies were not adequately powered to determine if a significant difference existed. Subsequently, a large randomized controlled trial of remdesivir use in COVID-19 showed no difference in liver biochemistries between treatment and control groups. Nonetheless, it is still recommended to avoid remdesivir in patients with ALT greater than 5 xULN and it should be discontinued if ALT increases above this level while on treatment.

Tocilizumab, an IL-6 antagonist that inhibits the pro-inflammatory cytokine cascade, has been used to treat COVID-19. Tocilizumab-induced liver injury has previously been documented in patients receiving it for rheumatoid arthritis, although these events are very rare. There have also been several case reports of apparent tocilizumab-DILI in patients with COVID-19, with one patient having aminotransferase elevations greater than 40 xULN; however, these cases are also very rare.
Tocilizumab is not recommended in patients with aminotransferase elevations greater than 5 xULN.

ALCOHOL-RELATED LIVER DISEASE AND THE CORONAVIRUS DISEASE-2019 PANDEMIC

In the years before the start of the COVID-19 pandemic, alcohol consumption and mortality from alcohol-associated liver disease were already on the rise. During the COVID-19 pandemic this rise has continued and even accelerated. Stay-at-home orders early in the pandemic led to social isolation, loss of support systems including addiction treatment programs, disruptions in work and education, and easier access to alcohol (eg, online, takeout), all factors that likely contributed to a significant increase in alcohol consumption and alcohol-associated liver disease during the pandemic. This manifested in drastic increases in listings for LT (7% increase) and LT (10% increase) for alcohol-associated liver disease. Transplant listing and LT for severe alcohol-associated hepatitis alone have also rapidly increased by over 50%, likely because of an increased burden of alcohol-related liver disease during the pandemic but also due to an unrelated nationwide shift away from strict policies requiring at least 6 months of alcohol abstinence before consideration of LT.

CORONAVIRUS DISEASE-2019 OUTCOMES IN LIVER DISEASE

Chronic Liver Disease and Cirrhosis

Several studies have shown that patients with CLD are not more likely to be diagnosed with COVID-19 and one study indicated that patients with cirrhosis might actually have a lower risk of testing positive for SARS-CoV-2. This is likely due to increased patient adherence to public health measures such as social distancing because it is unlikely that cirrhosis provides a protective effect. However, once patients with pre-existing liver disease of any etiology are diagnosed with COVID-19, they have higher rates of mortality than those without liver disease. Respiratory failure is the leading cause of death in patients with CLD and COVID-19, followed by liver-related causes. Outcomes seem to be correlated with severity of pre-existing cirrhosis, with odds ratio (OR) of death for Child-Pugh (CP)-A 1.90, CP-B 4.14 and CP-C 9.32. Outcomes for patients with decompensated cirrhosis and COVID-19 are extremely poor, with mortality rates as high as 80% for patients who require intensive care unit (ICU) admission. Although early mortality rates in patients with cirrhosis and COVID-19 are high, the rates of death and readmission at 90 days for patients who survive the acute insult return to baseline risk. Therefore, COVID-19 does not seem to result in long-term progression of liver disease outside of the acute infection period.

Viral Hepatitis

In 2017, the World Health Organization released the first Global Hepatitis Report and set a goal of eliminating viral hepatitis by 2030. Unfortunately, the necessary diversion of limited health care resources toward COVID-19 efforts limited the identification of new hepatitis B virus (HBV) and HCV infections and also limited access to treatment. This delay in viral hepatitis elimination and treatment because of the COVID-19 pandemic will certainly result in worse long-term viral hepatitis outcomes, with many patients progressing to cirrhosis and developing its accompanying complications such as hepatocellular carcinoma (HCC). A modeling study of 100 countries
predicted that a 1-year delay in the diagnosis of HCV could lead to an additional 44,800 cases of HCC and 72,300 deaths from HCV worldwide by 2030. Fortunately, the presence of HBV or HCV alone is not associated with COVID-19 mortality. In addition, antiviral therapy for HBV or HCV has not been associated with worsened COVID-19 outcomes.

**Nonalcoholic Steatohepatitis**

It has been well documented that older age, obesity and diabetes are associated with worsened COVID-19 outcomes. Given obesity and diabetes are often comorbid with NASH, there has been concern that patients with NASH are at increased risk of poor COVID-19-related outcomes. However, whether NASH independent of comorbidities increases the risk of severe COVID-19 and death is unclear. Several studies have suggested this might be true: nonalcoholic fatty liver disease (NAFLD) has been associated with worsened COVID-19 outcomes independent of obesity and other comorbidities. However, a large international cohort of 745 patients with cirrhosis and/or CLD failed to show an increased risk of mortality for NAFLD patients with COVID-19 (HR 1.01, 95% CI 0.57–1.79).

**Autoimmune Hepatitis**

There has also been concern that patients with autoimmune hepatitis (AIH) would be at increased risk of COVID-19-related morbidity and mortality. Interestingly, despite the use of immunosuppression, patients with AIH seem to have similar outcomes compared with patients with other CLD. Furthermore, AIH patients seem to have equivalent rates of COVID-19-related mortality when compared with the general population, and immunosuppression was not shown to be an independent risk factor for mortality or severe COVID-19.

**Liver Transplant Recipients**

Given their immunosuppressed state, it was feared that LT recipients would be at increased risk for severe COVID-19 and death. LT recipients are diagnosed with COVID-19 more frequently than non-transplant recipients. However, this is likely because of closer monitoring and a lower threshold for testing in this patient population as opposed to an increased risk of SARS-CoV-2 infection per se. LT recipients do seem to report more frequent gastrointestinal symptoms, with diarrhea occurring in 30% to 40%, but rates of elevated liver biochemistries are similar between LT and non-LT recipients. LT recipients are also more likely to have chronic kidney disease, type 2 diabetes mellitus, and obesity, which are well known risk factors for worse COVID-19-related outcomes. Yet, the studies to date have been conflicting. Several studies have reported high mortality rates in solid organ transplant recipients with COVID-19. However, after controlling for covariates including comorbidities, several other studies have suggested that LT recipients may not be at an increased risk of severe COVID-19 or death compared with non-LT recipients. This would be consistent with studies from the prior novel coronavirus outbreaks (SARS and MERS) that showed LT recipients were not at increased risk of morbidity and mortality compared with the general population. The suggestion of similar clinical outcomes between LT recipients and non-transplant recipients could be explained by the theorized protective effects of immunosuppression against a SARS-CoV-2-induced severe inflammatory host response, which is thought to be a primary driver in severe COVID-19. This is supported by data showing that high dose dexamethasone improves mortality in patients with severe COVID-19.
MANAGEMENT OF CHRONIC LIVER DISEASE DURING THE CORONAVIRUS DISEASE-2019 PANDEMIC

The optimal management of CLD during the COVID-19 pandemic is continually evolving as new data become available. In addition, management varies based on the presence or absence of active SAR-CoV-2 infection and on the underlying liver disease etiology (Table 1).

Autoimmune Hepatitis

**Without coronavirus disease-2019**

Given the risk of a flare/relapse with reduction or discontinuation of immunosuppression, providers should not adjust baseline immunosuppression for AIH in hopes of preventing COVID-19-related morbidity and mortality. A new diagnosis of AIH or a flare of existing AIH should be treated as clinically appropriate despite the risk of SARS-CoV-2 infection.

| Etiology               | Without COVID-19                                                                 | With COVID-19                                                                 |
|------------------------|---------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Autoimmune hepatitis   | • Do not preemptively reduce immunosuppression                                   | Mild COVID-19:                                                               |
|                        | • Treat new diagnosis or flare as clinically appropriate                        | • Do not reduce immunosuppression                                              |
|                        |                                                                                 | Moderate/severe COVID-19:                                                     |
|                        |                                                                                 | • Consider reducing immunosuppression by 25%-50%                              |
|                        |                                                                                 | • Consider reducing or stopping antimetabolite (eg, azathioprine, mycophenolate) |
| Chronic viral hepatitis| No change (ie, start or continue antiviral therapy as clinically appropriate) | HBV:                                                                         |
|                        |                                                                                 | • Initiate or continue treatment if indicated based on current HBV treatment guidelines |
|                        |                                                                                 | • Consider HBV prophylaxis if treating COVID-19 with immunosuppression (eg, dexamethasone, tocilizumab) |
|                        |                                                                                 | HCV:                                                                         |
|                        |                                                                                 | • Continue HCV therapy if already started                                     |
|                        |                                                                                 | • Postpone initiation of HCV therapy until after recovery from COVID-19       |
| NASH                   | No change                                                                       | No change                                                                    |
| PBC                    | No change                                                                       | No change                                                                    |
| PSC                    | No change                                                                       | No change                                                                    |
| ALD                    | No change                                                                       | No change                                                                    |

Abbreviations: ALD, alcohol-associated liver disease; CLD, chronic liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.
**With coronavirus disease-2019**

Given similar COVID-19-related outcomes in patients with AIH on immunosuppres-
sion compared with the general population, providers should not routinely reduce
immunosuppression in the setting of a new COVID-19 diagnosis. The severity of
COVID-19 should first be considered to determine the best next steps. For outpa-
tients with asymptomatic or mild COVID-19, immunosuppression should not be
adjusted. For patients with moderate to severe COVID-19 (ie, hospitalized and/or
ICU admission), the patient’s AIH disease history (such as frequency of prior re-
lapses) and fibrosis stage should be considered. For instance, a flare of AIH in a pa-
tient with cirrhosis/advanced fibrosis could result in hepatic decompensation;
therefore, the threshold for reducing immunosuppression in these patients should
be higher. If the decision is made to reduce immunosuppression, baseline doses
may be reduced by 25% to 50%. The patient should subsequently be monitored
closely for a AIH flare by checking liver enzymes daily in the hospitalized patient
and every 1 to 2 weeks once the patient is discharged. For patients on antimetabo-
lites such as azathioprine or mycophenolate with neutropenia and/or lymphopenia
associated with COVID-19, the antimetabolite dose should be reduced or
stopped and a white blood cell count with differential should be monitored every 1
to 2 weeks.

**Chronic Viral Hepatitis**

**Without coronavirus disease-2019**

Antiviral therapies have not been shown to increase the risk of severe COVID-19.
Therefore, antiviral therapy can be safely started and continued in HBV and HCV pa-
tients without COVID-19.

**With coronavirus disease-2019**

Given antiviral therapy does not worsen COVID-19 outcomes, continuation of antiviral
therapy for patients with HBV and HCV is also recommended for those with SARS-
CoV-2 infection. As initiation of therapy for HCV is not urgent, initiation of HCV therapy
for patients with COVID-19 should be postponed until the patient has recovered from
COVID-19. HBV therapy should be initiated despite active SARS-CoV-2 infection if
indicated based on current HBV treatment guidelines. Given the risk of reactivation of
HBV with immunosuppression, patients started on immunosuppression for COVID-19
with medications such as glucocorticoids or tocilizumab should be considered for
HBV prophylaxis.

**Other Chronic Liver Diseases (Nonalcoholic Steatohepatitis, Alcohol-Associated
Liver Disease, Primary Biliary Cholangitis, and Primary Sclerosing Cholangitis)**

The management strategies for many CLDs including NASH, alcohol-associated
liver disease, primary biliary cholangitis (PBC) and primary sclerosing cholangitis
(PSC) have not been significantly altered by the COVID-19 pandemic. Patients
with NASH should continue to be advised on risk factor control (diabetes, hyper-
lipidemia, and hypertension) and lifestyle changes to promote weight loss,
although it should be acknowledged that the pandemic has made exercise and
healthy eating habits more challenging for many. Patients with severe alcohol-
associated hepatitis can be considered for corticosteroid treatment if indicated.
Routine screening for colorectal cancer, gallbladder carcinoma and cholangiocar-
cinoma for patients with PSC should continue. Patients with PBC on treatment
(such as ursodiol) should continue on this even if they develop SARS-CoV-2
infection.
Telemedicine/Delivery of Care

Telemedicine, which is the delivery of health care from afar using technology, previously had slow uptake because of restrictive regulations, lack of reimbursement, lack of widespread Internet infrastructure, and resistance to change. However, shortly after the pandemic began there was a drastic increase in telemedicine use to help with mitigation efforts to slow the spread of COVID-19. Many restrictions on telemedicine services were lifted along with changes in reimbursement. As the pandemic progresses, it remains unseen how the delivery and use of telemedicine will continue to evolve. For liver-related care, telemedicine offers particular promise in the delivery of subspecialty hepatology care to patients in rural areas, those with limited transportation and financial means, and incarcerated persons. For example, the effort to eliminate viral hepatitis will likely need to rely heavily on telemedicine to reach these populations. However, there are many patients with CLD with socioeconomic disparities that may limit their access to high-speed Internet resulting in inadequate access to telemedicine. There will need to be a specific focus on improving Internet infrastructure, expanding access to computers and mobile devices, and education to improve technological competence, to ensure that these populations have equitable access to telemedicine.

CORONAVIRUS DISEASE-2019 VACCINATION

Patients with CLD have an increased risk of COVID-19 morbidity and mortality and should be prioritized for COVID-19 vaccination and booster doses. All of the available SARS-CoV-2 vaccines, including the messenger ribonucleic acid (mRNA) (Pfizer-BioNTech, Moderna) and adenoviral vector vaccines (Johnson & Johnson [J&J], AstraZeneca, Sputnik), are safe for patients with CLD and there are no contraindications for their use in this patient population. Thus, patients should be vaccinated as soon as they are eligible and a vaccine is available to them. COVID-19 vaccination does not require delaying or discontinuing therapy for any CLD such as antiviral therapy for HBV/HCV or immunosuppression for AIH. Routine non-COVID-19 vaccines (such as vaccination against hepatitis A or HBV) also do not need to be delayed while patients are receiving the COVID-19 vaccine series and can be given as scheduled. For further guidance regarding COVID-19 vaccination in patients with liver disease, AASLD has created an expert panel consensus statement that will be continually updated as new data arise.

Cirrhosis/Chronic Liver Disease

Patients with cirrhosis have been shown to have impaired responses to non-COVID-19 vaccines such as pneumococcus and HBV, likely due to immune dysfunction seen in cirrhosis. Although there are limited data currently on the efficacy of COVID-19 vaccines in patients with CLD, the available data suggest a similar impaired but still significantly protective response to COVID-19 vaccines. A large study from the Veterans Affairs system propensity matched 20,037 patients with CLD who had received one dose of an mRNA vaccine (Moderna or Pfizer-BioNTech) with 20,037 control patients who had not been vaccinated. At 28 days after one dose, there was a 64% reduction in SARS-CoV-2 infections and 100% reduction in hospitalization and death in patients with CLD. A second dose provided additional protection with a 78% reduction in SARS-CoV-2 infections and 100% protection against hospitalization and death. This contrasts with a 94%-95% reduction in SARS-CoV-2 infections after two doses of an mRNA vaccine in the general population. The severity of liver disease is also associated with impaired response to vaccination. Vaccinated patients with decompensated cirrhosis
had only a 50% reduction in new SARS-CoV-2 infections compared with 66% in patients with compensated cirrhosis.69

**Liver Transplantation Recipients**

Data on COVID-19 immunization in LT recipients have shown the vaccines to be safe and effective at preventing hospitalization and death.63 Available data do not show an increased risk of alloimmunity and graft rejection.70 It is important to note that none of the available vaccines contain live SARS-CoV-2; therefore, replication of SARS-CoV-2 after vaccination is not possible even in immunocompromised patients. However, compared with immunocompetent individuals, LT recipients have lower levels of anti-spike antibody production after COVID-19 vaccination and a quicker decline in antibody levels over time.71 This is similar to prior studies that have shown LT recipients have a poor response to non-COVID-19 vaccinations.70 Risk factors for poor antibody formation after COVID-19 vaccination in this population include older age, chronic kidney disease, use of high dose steroids and use of mycophenolate mofetil.72 Despite this, it is not recommended to reduce immunosuppression to improve immune response to COVID-19 vaccination given the risk of acute cellular rejection.63 The antibody response from mRNA COVID-19 vaccination can be improved with additional doses.73,74 As a result, current guidelines recommend a primary series of three doses for the mRNA vaccines in immunocompromised patients including LT recipients followed by one or more booster doses (Table 2).63 For patients who received the J&J vaccine, the primary series should consist of a second dose of the J&J vaccine or a dose of an mRNA vaccine followed by one or more booster doses. Given that antibody formation after vaccination is greater for patients with cirrhosis compared with post LT patients, candidates for LT should be vaccinated before transplant whenever possible.63,75 Potential live liver donors should also be encouraged to undergo

| Table 2 General guidelines for COVID-19 vaccination for adults in the United States with CLD and LT recipients |
|---------------------------------------------------------------|
| **Number/Manufacturer of Primary Series** | **Booster** |
| CLD | 2 Pfizer-BioNTech mRNA or Pfizer-BioNTech mRNA or 2 Moderna mRNA or Moderna mRNA or 2 Novavax adjuvanted or J&J/Janssen adenoviral vector | Bivalent Pfizer-BioNTech or Moderna mRNA ≥2 months after primary series |
| AIH on immunosuppression | 3 Pfizer-BioNTech mRNA or Moderna mRNA or Moderna mRNA or Moderna mRNA or Moderna mRNA or adenoviral vector followed by any mRNA vaccine | Bivalent Pfizer-BioNTech or Moderna mRNA ≥2 months after primary series |
| LT recipients | 3 Pfizer-BioNTech mRNA or Moderna mRNA or Moderna mRNA or Moderna mRNA or Moderna mRNA or adenoviral vector followed by any mRNA vaccine | Bivalent Pfizer-BioNTech or Moderna mRNA ≥2 months after primary series |

*Abbreviations: AIH, autoimmune hepatitis; CLD, chronic liver disease; LT, liver transplant  
See CDC website for additional details, including dose intervals and pediatric recommendations: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.*

* Janssen COVID-19 vaccine should only be used in certain limited situations; mRNA primary vaccine series preferred whenever possible.
vaccination before donation. Even if LT is likely to happen before completion of the vaccine series, COVID-19 vaccination should continue after transplantation. Any additional vaccine doses that need to be completed post-LT can be given at the earliest appropriate interval following transplant (around 4 weeks’ post-LT). If COVID-19 vaccination cannot be started before transplant, the optimal timing for vaccination is likely at least 3 months post-LT when immunosuppression is lower to allow for better antibody formation; however, it is possible to begin vaccination as early as 4 weeks post-LT.63

Table 2 shows general guidelines for COVID-19 vaccination in adults with CLD and LT recipients. Recommendations for vaccination in LT recipients are likely to change as new data become available. Additional booster doses may be recommended for both transplant recipients and the general population as immunity naturally wanes and new viral variants emerge. Check the CDC website for the latest available recommendations: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#immunocompromised.

Liver Transplantation Candidates

COVID-19 vaccines have been proven to be safe and effective at preventing hospitalization and death in patients with cirrhosis and in LT recipients.63 When possible, vaccination should occur before transplant due to better antibody formation and protection against poor outcomes after vaccination in patients with cirrhosis compared with LT recipients.75 Many transplant centers have required COVID-19 and other vaccinations before listing for liver transplant. These policies are clinically and ethically justified but remain at the discretion of each transplant center.76

Autoimmune Hepatitis

Patients with AIH on immunosuppression have also been shown to have a poor response to vaccinations against non-COVID-19 diseases.70 Early data on COVID-19 vaccination for patients on immunosuppression also indicate an impaired immune response in this population.77 Therefore, it is currently recommended that immunosuppressed patients, including patients with AIH on immunosuppression, receive a three-dose primary series of an mRNA vaccine plus one or more booster doses (see Table 2).78

There have been several case reports of a rare AIH-like liver injury following COVID-19 vaccination.79–81 A systematic review by Chow and colleagues summarized the existing case reports and series that included 32 patients with an AIH-like syndrome following an mRNA or Oxford-AstraZeneca COVID-19 vaccine.82 Several of these patients did not meet criteria for AIH and likely just had hepatocellular or cholestatic DILI to the vaccine without autoimmune features. There was also a small subset of patients (n = 4) who had a prior diagnosis of AIH that was in remission before receiving the vaccine and then developed a flare following COVID-19 vaccination.83 Given the low incidence, it has not been determined whether these rare events are simply coincidental or causally related to the vaccine. This rare potential risk should not discourage COVID-19 vaccination, even in those with preexisting AIH or CLD.

LIVER TRANSPLANTATION AND CORONAVIRUS DISEASE-2019 Severe Acute Respiratory Syndrome Coronavirus 2-Positive Liver Transplantation Recipient

LT recipients require high doses of immunosuppression immediately post-transplant to prevent rejection and there is significant concern for worsened post-LT outcomes if a transplant recipient were to become infected with SARS-CoV-2 at the time of
transplant. As a result, it is recommended that all recipients be tested for SARS-CoV-2 before transplant. There have been several reports of successful living donor LT in SARS-CoV-2-positive recipients after a minimum of 14 days from positive SARS-CoV-2 PCR. However, available data suggest that the risk of postoperative morbidity and mortality related to recent COVID-19 can remain high for much longer than 14 days after acute infection and seems to remain particularly elevated for up to 7 weeks post-infection. Therefore, except in extreme circumstances, patients with active/recent COVID-19 should not undergo LT. The specific circumstances and urgency of the recipient should be considered when deciding whether to proceed with LT.

**Severe Acute Respiratory Syndrome Coronavirus 2-Positive Donor**

If an organ from a SARS-CoV-2-positive donor is transplanted into a SARS-CoV-2-negative recipient, there is a theoretic risk of SARS-CoV-2 transmission from the donor to recipient. To date, all of the reported cases of SARS-CoV-2 transmission from a COVID-19-positive donor have occurred in lung transplantation and there have been no proven or suspected cases of donor-to-recipient SARS-CoV-2 transmission in non-lung transplants. In fact, several case reports have described the successful use of SARS-CoV-2 positive donors without documented transmission to the transplant recipient in non-lung solid organ transplant. Given the limited data that exist, no recommendation regarding the risk of SARS-CoV-2 transmission to the recipient can be made. Given the concerns about possible donor-to-recipient transmission, it is recommended that all potential donors be tested for SARS-CoV-2 before LT. However, SARS-CoV-2 PCR may remain positive for months after resolution of infection despite a patient no longer being infectious. Although a lack of infiltrates on chest imaging or a SARS-CoV-2 diagnosis greater than 10 days earlier may indicate inactive infection, it can often be hard to differentiate between active and inactive infection. The cycle time (number of amplification cycles needed to produce a positive PCR test) may be helpful to differentiate active from inactive infection. Low cycle times reflect higher viral load, whereas high cycle times reflect lower viral load, possibly indicating inactive infection.

The decision to proceed with transplantation using a SARS-CoV-2-positive donor should consider the severity and timing of COVID-19 in the potential donor and the urgency of the potential recipient. Donor organ quality should also be considered independently from the risk of donor-to-recipient viral transmission.

**Management of the Liver Transplantation Recipient without Coronavirus Disease-2019**

Given the risk of acute cellular rejection, maintenance immunosuppression should be continued and the doses should not be lowered. Patients who develop acute rejection should also continue to receive the standard of care with high dose immunosuppression to preserve graft function.

**Management of the Liver Transplantation Recipient with Coronavirus Disease-2019**

For LT recipients with an active SARS-CoV-2 infection, the decision to modify immunosuppression and dosing should be individualized based on history of rejection, the risk of future rejection, length of time post-LT and the severity of COVID-19. Tacrolimus has been associated with better survival in transplant recipients with COVID-19 and generally should not be decreased or stopped. Mycophenolate, however, has been found to be an independent risk factor for severe COVID-19 in LT recipients.
and decreasing or stopping it is a reasonable approach to managing LT recipients with moderate/severe COVID-19. 47

**Outpatient/Mild Coronavirus Disease-2019 Management**

Immunosuppression should not be adjusted for LT recipients with mild COVID-19. There are several treatment options available for patients who are diagnosed with COVID-19 including nirmatrelvir-ritonavir (Paxlovid), molnupiravir, monoclonal antibodies and remdesivir. Nirmatrelvir-ritonavir is a combination of oral protease inhibitors that blocks SARS-CoV-2 protease activity. In a randomized controlled trial, it was shown to be highly effective at reducing rates of hospitalization or death (89% reduction compared with placebo). 95 Nirmatrelvir-ritonavir is not recommended in patients with severe renal (eGFR 30 mL/min) or severe liver (CP-C) impairment. There are significant drug interactions with nirmatrelvir-ritonavir, especially calcineurin inhibitors, which may lead to dangerously high levels of these drugs in some transplant recipients. For patients who are not candidates for nirmatrelvir-ritonavir, other therapies that can be considered are monoclonal antibodies, remdesivir and molnupiravir.

**Inpatient/Moderate–Severe Coronavirus Disease-2019 Management**

Given the association of antimetabolite medications and worsened COVID-19 outcomes, it is recommended that doses of azathioprine or mycophenolate should be lowered in moderate to severe COVID-19, including patients hospitalized for COVID-19. 12 Glucocorticoids may be beneficial in severe COVID-19 and have not been shown to worsen outcomes; therefore, immunosuppression consisting of glucocorticoids should not be routinely adjusted. 96 In patients who develop neutropenia and/or lymphopenia (absolute lymphocyte count <1000 cells/microL for adults) due to COVID-19, the dose of azathioprine or mycophenolate should be reduced and labs (white blood cell count with differential and liver biochemistries) should be checked every 1 to 2 weeks to monitor for rejection and improvement in neutropenia and/or lymphopenia.

**SUMMARY**

The COVID-19 pandemic has had a substantial impact on patients with CLD and LT recipients and has significantly altered the care of these patients. Vaccination against COVID-19 is effective at protecting patients with CLD and LT recipients from adverse outcomes and is safe in these patients; however, vaccine efficacy may be reduced in LT recipients and other immunosuppressed patients. COVID-19 has challenged the transplant community and the decisions about the use of potential donors with recent or current SARS-CoV-2 infection and when it is safe to proceed with LT in potential recipients with SARS-CoV-2 infection.

**CLINICS CARE POINTS**

- Compared to the general population, patients with chronic liver disease and liver transplant recipients are at a significantly increased risk of poor outcomes due to COVID-19.
- For patients without active COVID-19 infection who are on immunosuppression for autoimmune hepatitis or after liver transplantation, the doses of immunosuppressive medications should not be routinely altered in an attempt to prevent COVID-19 complications.
- In addition, flares of autoimmune hepatitis or episodes of post liver transplant rejection should be treated as clinically appropriate.
Although patients with chronic liver disease and liver transplant recipients may have an impaired response to COVID-19 vaccination, vaccination in these patients has still been proven to be safe and effective at preventing morbidity and mortality due to COVID-19. Antibody formation after vaccination has been shown to be greater in patients with chronic liver disease as compared to liver transplant recipients, therefore COVID-19 vaccination prior to transplant should be prioritized.

DISCLOSURE

The authors have no relevant commercial or financial conflicts of interest and no funding was received for this article.

REFERENCES

1. Hundt MA, Deng Y, Ciarleglio MM, et al. Abnormal liver tests in COVID-19: a retrospective Observational cohort study of 1,827 patients in a Major U.S. Hospital Network. Hepatology 2020;72(4):1169–76.
2. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020;323(20):2052–9.
3. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020;5(5):428–30.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.
5. Phipps MM, Barraza LH, LaSota ED, et al. Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large U.S. Cohort. Hepatology 2020;72(3):807–17.
6. Kulkarni AV, Kumar P, Tevethia HV, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther 2020;52(4):584–99.
7. Bloom PP, Meyerowitz EA, Reinus Z, et al. Liver biochemistries in hospitalized patients with COVID-19. Hepatology 2021;73(3):890–900.
8. Singh S, Khan A. Clinical Characteristics and outcomes of coronavirus disease 2019 among patients with Preexisting liver disease in the United States: a multicenter Research Network study. Gastroenterology 2020;159(2):768–71.e3.
9. Sonzogni A, Previtali G, Seghezzi M, et al. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. Liver Int 2020;40(9):2110–6.
10. Papic N, Pangercic A, Vargovic M, et al. Liver involvement during influenza infection: perspective on the 2009 influenza pandemic. Influenza Other Respir Viruses 2012;6(3). e2-5.
11. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.
12. Fix O, Fontana R, Bezerra J, et al. Clinical best Practice Advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Available at: http://www.aasld.org/ClinicalInsights. Accessed April 19, 2022.
13. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020;581(7807):215–20.
14. Pirola CJ, Sookoian S. SARS-CoV-2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID-19. Liver Int 2020;40(8):2038–40.
15. Lagana SM, Kudose S, Iuga AC, et al. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. Mod Pathol 2020;33(11):2147–55.
16. Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans up-regulates the novel enzyme angiotensin converting enzyme 2. Gut 2005;54(12):1790–6.
17. Fondevila MF, Mercado-Gómez M, Rodríguez A, et al. Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. J Hepatol 2021;74(2):469–71.
18. Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect 2020;9(1):601–4.
19. Bassendine MF, Bridge SH, McAughan GW, et al. COVID-19 and comorbidities: a role for dipeptidyl peptidase 4 (DPP4) in disease severity? J Diabetes 2020;12(9):649–58.
20. Kaji K, Yoshiji H, Ikenaka Y, et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol Mar 2014;49(3):481–91.
21. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost 2020;18(7):1559–61.
22. Diaz LA, Idalsoaga F, Cannistra M, et al. High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: a systematic review and meta-analysis of autopsy data. World J Gastroenterol 2020;26(48):7693–706.
23. Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol 2020;18(7):1561–6.
24. Roth NC, Kim A, Vitkovski T, et al. Post-COVID-19 cholangiopathy: a novel Entity. Am J Gastroenterol 2021;116(5):1077–82.
25. Faruqui S, Okoli FC, Olsen SK, et al. Cholangiopathy after severe COVID-19: clinical features and Prognostic Implications. Am J Gastroenterol 2021;116(7):1414–25.
26. Durazo FA, Nicholas AA, Mahaffey JJ, et al. Post-Covid-19 cholangiopathy-A new indication for liver transplantation: a case report. Transplant Proc 2021;53(4):1132–7.
27. Laurent L, Lemaitre C, Minello A, et al. Cholangiopathy in critically ill patients surviving beyond the intensive care period: a multicentre survey in liver units. Aliment Pharmacol Ther 2017;46(11–12):1070–6.
28. Montastruc F, Thuriot S, Durrieu G. Hepatic Disorders with the Use of remdesivir for coronavirus 2019. Clin Gastroenterol Hepatol 2020;18(12):2835–6.
29. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 - Final report. N Engl J Med 2020;383(19):1813–26.
30. Mahamid M, Mader R, Salafi R. Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions. Clin Pharm 2011;3:39–43.
31. Muhović D, Bojović J, Bulatović A, et al. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. Liver Int 2020;40(8):1901–5.
32. Deutsch-Link S, Jiang Y, Peery AF, et al. Alcohol-associated liver disease mortality increased from 2017 to 2020 and accelerated during the COVID-19 pandemic. Clin Gastroenterol Hepatol 2022. https://doi.org/10.1016/j.cgh.2022.03.017.
33. Moon AM, Curtis B, Mandrekar P, et al. Alcohol-associated liver disease before and after COVID-19: an Overview and Call for Ongoing Investigation. Hepatol Commun 2021;5(9):1616–21.

34. Cholankeril G, Goli K, Rana A, et al. Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the USA. Hepatology 2021;74(6):3316–29.

35. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584(7821):430–6.

36. Ioannou GN, Liang PS, Locke E, et al. Cirrhosis and severe acute respiratory syndrome coronavirus 2 infection in US Veterans: risk of infection, hospitalization, ventilation, and mortality. Hepatology 2021;74(1):322–35.

37. Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol 2021;74(3):567–77.

38. Ge J, Pletcher MJ, Lai JC, et al. Outcomes of SARS-CoV-2 infection in patients with chronic liver disease and cirrhosis: a national COVID cohort Collaborative study. Gastroenterology 2021;161(5):1487–501.e5.

39. Bajaj JS, Garcia-Tsao G, Wong F, et al. Cirrhosis is associated with high mortality and readmissions over 90 Days Regardless of COVID-19: a multicenter study. Liver Transpl 2021;27(9):1343–7.

40. Global hepatitis report 2017. Geneva: World Health Organization. Available at: cdc.gov/vaccines/adults/rec-vac/health-conditions/liver-disease.html. Accessed April 20, 2022.

41. Blach S, Kondili LA, Aghemo A, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol 2021;74(1):31–6.

42. Yip TC, Wong VW, Lui GC, et al. Current and Past infections of HBV do not increase mortality in patients with COVID-19. Hepatology 2021;74(4):1750–65.

43. Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol 2020;73(2):451–3.

44. Sachdeva S, Khandait H, Kopel J, et al. NAFLD and COVID-19: a Pooled analysis. SN Compr Clin Med 2020;2(12):2726–9.

45. Marjot T, Buescher G, Sebode M, et al. SARS-CoV-2 infection in patients with autoimmune hepatitis. J Hepatol 2021;74(6):1335–43.

46. Efe C, Dhanasekaran R, Lammert C, et al. Outcome of COVID-19 in patients with autoimmune hepatitis: an international multicenter study. Hepatology 2021;73(6):2099–109.

47. Colmenero J, Rodriguez-Perálvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol 2021;74(1):148–55.

48. Ravanran R, Callaghan CJ, Mumford L, et al. SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: a national cohort study. Am J Transplant 2020;20(11):3008–18.

49. Webb GJ, Marjot T, Cook JA, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol 2020;5(11):1008–16.

50. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant 2020;20(7):1800–8.

51. Rabiee A, Sadowski B, Adeniji N, et al. Liver injury in liver transplant recipients with coronavirus disease 2019 (COVID-19): U.S. Multicenter Experience. Hepatology 2020;72(6):1900–11.
52. Webb GJ, Moon AM, Barnes E, et al. Determining risk factors for mortality in liver transplant patients with COVID-19. Lancet Gastroenterol Hepatol 2020;5(7): 643–4.

53. D’Antiga L. Coronaviruses and immunosuppressed patients: the facts during the Third Epidemic. Liver Transpl 2020;26(6):832–4.

54. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020;26(10):1636–43.

55. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med 2021;384(8):693–704.

56. Gerussi A, Rigamonti C, Elia C, et al. Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients. Hepatol Commun 2020. https://doi.org/10.1002/hep4.1557.

57. Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148(1):215–9.

58. Chen LF, Mo YQ, Jing J, et al. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int J Rheum Dis 2017;20(7):859–69.

59. Fix OK, Serper M. Telemedicine and Telehepatology during the COVID-19 pandemic. Clin Liver Dis (Hoboken) 2020;15(5):187–90.

60. Mann DM, Chen J, Chunara R, et al. COVID-19 transforms health care through telemedicine: evidence from the field. J Am Med Inform Assoc 2020;27(7): 1132–5.

61. Serper M, Cubell AW, Deleener ME, et al. Telemedicine in liver disease and beyond: can the COVID-19 Crisis lead to action? Hepatology 2020;72(2):723–8.

62. Wegermann K, Wilder JM, Parish A, et al. Racial and socioeconomic disparities in Utilization of Telehealth in patients with liver disease during COVID-19. Dig Dis Sci 2022;67(1):93–9.

63. Fix O, Kaul D, et al. AASLD expert panel consensus statement: vaccines to prevent COVID-19 in patients with liver disease. https://aasld.org/VaccineDocument.

64. Fix OK, Blumberg EA, Chang KM, et al. American association for the study of liver diseases expert panel consensus statement: vaccines to prevent coronavirus disease 2019 infection in patients with liver disease. Hepatology 2021;74(2): 1049–64.

65. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 2020;383(27):2603–15.

66. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384(5):403–16.

67. McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 2000;181(2):757–60.

68. Aggeletopoulou I, Davoulou P, Konstantakis C, et al. Response to hepatitis B vaccination in patients with liver cirrhosis. Rev Med Virol 2017;27(6). https://doi.org/10.1002/rmv.1942.

69. John BV, Deng Y, Scheinberg A, et al. Association of BNT162b2 mRNA and mRNA-1273 vaccines with COVID-19 infection and hospitalization among patients with cirrhosis. JAMA Intern Med 2021;181(10):1306–14.

70. Chong PP, Avery RK. A Comprehensive review of immunization Practices in solid organ transplant and Hematopoietic Stem cell transplant recipients. Clin Ther 2017;39(8):1581–98.
71. Caballero-Marcos A, Salcedo M, Alonso-Fernández R, et al. Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared with immunocompetent patients. Am J Transpl 2021;21(8):2876–84.

72. Rabinowich L, Grupper A, Baruch R, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol 2021;75(2):435–8.

73. Kamar N, Abravanel F, Marion O, et al. Three doses of an mRNA covid-19 vaccine in solid-organ transplant recipients. N Engl J Med 2021;385(7):661–2.

74. Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a Third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med 2021;385(13):1244–6.

75. Rueether DF, Schaub GM, Duengelhoef PM, et al. SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients. Clin Gastroenterol Hepatol 2022;20(1):162–72.e9.

76. Kates OS, Stohs EJ, Pergam SA, et al. The limits of refusal: an ethical review of solid organ transplantation and vaccine hesitancy. Am J Transpl 2021;21(8):2637–45.

77. Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 2022;376:e068632.

78. CDC. COVID-19 Vaccines for moderately or severely immunocompromised people. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html. Accessed April 14, 2022.

79. Bril F, Fettig DM. Reply to: "Comment on "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty? J Hepatol 2021;75(4):996–7.

80. McShane C, Kiat C, Rigby J, et al. The mRNA COVID-19 vaccine - a rare trigger of autoimmune hepatitis? J Hepatol 2021;75(5):1252–4.

81. Rocco A, Sgamato C, Compare D, et al. Autoimmune hepatitis following SARS-CoV-2 vaccine: may not be a casualty. J Hepatol 2021;75(3):728–9.

82. Cow KW, Pham NV, Ibrahim BM. Autoimmune hepatitis-like syndrome following COVID-19 vaccination: a systemic review of the literature. Dig Dis Sci 2022.

83. Shroff H, Satapathy SK, Crawford JM, et al. Liver injury following SARS-CoV-2 vaccination: a multicenter case series. J Hepatol 2022;76(1):211–4.

84. Nepogodiev D, Simoes J, Li E, et al. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. Anaesthesia 2021;76(6):748–58.

85. Kaul DR, Vece G, Blumberg E, et al. Ten years of donor-derived disease: a report of the disease transmission advisory committee. Am J Transplan 2021;21(2):689–702.

86. Kaul DR, Valesano AL, Petrie JG, et al. Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing. Am J Transpl 2021;21(8):2885–9.

87. Kulkarni AV, Parthasarathy K, Kumar P, et al. Early liver transplantation after COVID-19 infection: the first report. Am J Transplant 2021;21(6):2279–84.

88. Koval CE, Poggio ED, Lin YC, et al. Early success transplanting kidneys from donors with new SARS-CoV-2 RNA positivity: a report of 10 cases. Am J Transpl 2021;21(11):3743–9.

89. Sigler R, Shah M, Schnickel G, et al. Successful heart and kidney transplantation from a deceased donor with PCR positive COVID-19. Transpl Infect Dis 2021;23(5):e13707.
90. de la Villa S, Valerio M, Salcedo M, et al. Heart and liver transplant recipients from donor with positive SARS-CoV-2 RT-PCR at time of transplantation. Transpl Infect Dis 2021;23(5):e13664.

91. Meshram HS, Kute VB, Patel H, et al. A case report of successful kidney transplantation from a deceased donor with terminal COVID-19-related lung damage: Ongoing dilemma between discarding and accepting organs in COVID-19 era. Transpl Infect Dis 2021;23(5):e13683.

92. Cariani L, Orena BS, Ambrogi F, et al. Time length of Negativization and cycle threshold Values in 182 health care Workers with covid-19 in milan, Italy: an Observational cohort study. Int J Environ Res Public Health 2020;(15):17. https://doi.org/10.3390/ijerph17155313.

93. Fix OK, Hameed B, Fontana RJ, et al. Clinical best Practice Advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology 2020;72(1):287–304.

94. Belli LS, Fondevila C, Cortesi PA, et al. Protective role of Tacrolimus, Deleterious role of age and comorbidities in liver transplant recipients with covid-19: results from the ELITA/ELTR Multi-center European study. Gastroenterology 2021; 160(4):1151–63.e3.

95. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, Nonhospitalized adults with covid-19. N Engl J Med 2022;386(15):1397–408.

96. Coronavirus NIH. Disease 2019 (COVID-19) treatment guidelines. Available at: http://www.covid19treatmentguidelines.nih.gov. Accessed April 23, 2022.